Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression, according to the results of a phase I study conducted by researchers at Mass General Cancer Center.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

Physicians and researchers at Winship Cancer Institute of Emory University announced they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractory multiple myeloma.

May 22, 2026

Vol.52 No.20

Clinical Roundup

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Drugs & Targets

Sartorius launches platform to boost efficiency in cell therapy production

Sartorius is launching an integrated system for the production and quality control of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR T therapies.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Citius Oncology announced positive topline safety and efficacy results from an investigator‑initiated phase I trial evaluating Lymphir (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma.

March 13, 2026

Vol.52 No.10

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

YOU MAY BE INTERESTED IN

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

Sartorius launches platform to boost efficiency in cell therapy production

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login